Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trough anti-Xa activity after intermediate dose nadroparin for thrombosis prophylaxis in critically ill patients with COVID-19 and acute kidney injury.

Scientific reports·2022
Same author

Clinically relevant potential drug-drug interactions in intensive care patients: A large retrospective observational multicenter study.

Journal of critical care·2020
Same author

Voluntarily reported prescribing, monitoring and medication transfer errors in intensive care units in The Netherlands.

International journal of clinical pharmacy·2020
Same author

Yttrium-90 radioembolization for colorectal cancer liver metastases: a prospective cohort study on circulating angiogenic factors and treatment response.

EJNMMI research·2016
Same author

P51. Pregnancy stimulates cerebellar hemangioblastoma growth in von Hippel-Lindau disease.

Pregnancy hypertension·2015
Same author

Effects of medetomidine and ketamine on the regional cerebral blood flow in cats: a SPECT study.

Veterinary journal (London, England : 1997)·2011

Related Experiment Video

Updated: Jun 22, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Microsphere radioembolization of liver malignancies: current developments.

W Bult1, M A D Vente, B A Zonnenberg

  • 1Department of Radiology and Nuclear Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of
|June 13, 2009
PubMed
Summary

Radioactive microspheres offer promising liver cancer treatment. Newer options like holmium-166 and rhenium-188 microspheres improve imaging for better therapy planning and patient follow-up compared to yttrium-90.

More Related Videos

Fabricating and Labeling Microbubbles with Fluorescent and Radioactive Tracers
10:40

Fabricating and Labeling Microbubbles with Fluorescent and Radioactive Tracers

Published on: January 24, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Jun 22, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Fabricating and Labeling Microbubbles with Fluorescent and Radioactive Tracers
10:40

Fabricating and Labeling Microbubbles with Fluorescent and Radioactive Tracers

Published on: January 24, 2025

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiology

Background:

  • Hepatic malignancies have a high global incidence, exceeding 1 million cases annually.
  • Current liver-directed therapies include intra-arterial administration of radioactive particles.
  • Yttrium-90 ((90)Y) microspheres are widely used for radioembolization, showing promising response rates.

Purpose of the Study:

  • To review the current status and developments of radioactive microspheres for liver malignancy treatment.
  • To highlight the limitations of Yttrium-90 ((90)Y) microspheres in imaging.
  • To discuss the advancements and clinical potential of holmium-166 ((166)Ho) and rhenium-188 ((188)Re) microspheres.

Main Methods:

  • Review of existing literature on radioactive microsphere therapy for liver malignancies.
  • Comparison of Yttrium-90 ((90)Y), Holmium-166 ((166)Ho), and Rhenium-188 ((188)Re) microsphere properties.
  • Analysis of preclinical and clinical data for novel microsphere applications.

Main Results:

  • Yttrium-90 ((90)Y) microspheres are effective but limit imaging quality for treatment planning and follow-up.
  • Holmium-166 ((166)Ho) and Rhenium-188 ((188)Re) microspheres offer therapeutic beta-emission and gamma-emission for imaging.
  • Holmium-166 ((166)Ho) also allows for magnetic resonance imaging (MRI) due to its paramagnetic properties.

Conclusions:

  • Newer radioactive microspheres like (166)Ho and (188)Re offer significant advantages over (90)Y by enabling superior imaging.
  • (166)Ho-loaded poly(L-lactic acid) microspheres have shown promise in preclinical studies.
  • Early clinical results for (188)Re microspheres are encouraging, suggesting improved therapeutic strategies for liver malignancies.